Report Content
Chapter 1 Methodology & Scope
1.1 Methodology
1.2 Base estimates and working
1.2.1 North America
1.2.2 Europe
1.2.3 Asia Pacific
1.2.4 Latin America
1.2.5 MEA
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Demulcent eye drops industry 3600 synopsis, 2017 - 2030
2.1.1 Business trends
2.1.2 Active pharmaceutical ingredient type trends
2.1.3 Drug formulation trends
2.1.4 Medication type trends
2.1.5 Distribution channel trends
2.1.6 Regional trends
Chapter 3 Demulcent Eye Drops Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2030
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Surge in the prevalence of eye diseases
3.3.1.2 Innovative drug formulation launches due to advancements in technology
3.3.1.3 Growing awareness regarding eye diseases among population base
3.3.2 Industry pitfalls & challenges
3.3.2.1 Side-effects associated with demulcent eye drops solutions
3.3.2.2 Numerous challenges encountered during treatment of various eye diseases
3.4 Growth potential analysis
3.4.1 By active pharmaceutical ingredient type
3.4.2 By drug formulation
3.4.3 By medication type
3.4.4 By distribution channel
3.5 COVID- 19 impact analysis
3.6 Industry ecosystem analysis
3.6.1 Raw materials and component suppliers
3.6.2 Manufacturers
3.6.3 Distribution channel analysis
3.6.4 End users
3.6.5 Vendor matrix
3.7 Epidemiological analysis
3.8 Pipeline analysis
3.9 Technology and innovation landscape, 2021
3.10 Regulatory landscape
3.10.1 U.S.
3.10.2 Europe
3.10.3 Asia Pacific
3.11 Porter's analysis
3.11.1 Bargaining power of suppliers
3.11.2 Bargaining power of buyers
3.11.3 Threat of new entrants
3.11.4 Threat of substitutes
3.11.5 Industry rivalry
3.12 Competitive landscape, 2021
3.12.1 Alcon Inc.
3.12.2 Bausch Health Companies Inc.
3.12.3 Johnson and Johnson Services, Inc.
3.12.4 Company matrix analysis, 2021
3.13 PESTEL analysis
Chapter 4 Demulcent Eye Drops Market, By Active Pharmaceutical Ingredient Type
4.1 Key segment trends
4.2 Cellulose Derivatives
4.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.3 Dextran 70
4.3.1 Market size, by region, 2017 - 2030 (USD Million)
4.4 Polyols
4.4.1 Market size, by region, 2017 - 2030 (USD Million)
4.5 Polymers
4.5.1 Market size, by region, 2017 - 2030 (USD Million)
4.6 Others
4.6.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 5 Demulcent Eye Drops Market, By Drug Formulation
5.1 Key segment trends
5.2 Preservative Based
5.2.1 Market size, by region, 2017 - 2030 (USD Million)
5.3 Non-Preservative Based
5.3.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 6 Demulcent Eye Drops Market, By Medication Type
6.1 Key segment trends
6.2 Over-the-counter (OTC)
6.2.1 Market size, by region, 2017 - 2030 (USD Million)
6.3 Prescription
6.3.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 7 Demulcent Eye Drops Market, By Distribution Channel
7.1 Key segment trends
7.2 Hospital Pharmacies
7.2.1 Market size, by region, 2017 - 2030 (USD Million)
7.3 Retail Pharmacies
7.3.1 Market size, by region, 2017 - 2030 (USD Million)
7.4 Online Pharmacies
7.4.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 8 Demulcent Eye Drops Market, By Region
8.1 Key regional trends
8.2 North America
8.2.1 Market size, by country, 2017 - 2030 (USD Million)
8.2.2 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.2.3 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.2.4 Market size, by medication type, 2017 - 2030 (USD Million)
8.2.5 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.2.6 U.S.
8.2.6.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.2.6.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.2.6.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.2.6.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.2.7 Canada
8.2.7.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.2.7.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.2.7.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.2.7.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.3 Europe
8.3.1 Market size, by country, 2017 - 2030 (USD Million)
8.3.2 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.3.3 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.3.4 Market size, by medication type, 2017 - 2030 (USD Million)
8.3.5 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.3.6 Germany
8.3.6.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.3.6.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.3.6.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.3.6.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.3.7 UK
8.3.7.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.3.7.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.3.7.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.3.7.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.3.8 France
8.3.8.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.3.8.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.3.8.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.3.8.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.3.9 Spain
8.3.9.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.3.9.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.3.9.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.3.9.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.3.10 Italy
8.3.10.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.3.10.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.3.10.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.3.10.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.4 Asia Pacific
8.4.1 Market size, by country, 2017 - 2030 (USD Million)
8.4.2 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.4.3 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.4.4 Market size, by medication type, 2017 - 2030 (USD Million)
8.4.5 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.4.6 China
8.4.6.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.4.6.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.4.6.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.4.6.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.4.7 Japan
8.4.7.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.4.7.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.4.7.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.4.7.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.4.8 India
8.4.8.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.4.8.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.4.8.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.4.8.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.4.9 Australia
8.4.9.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.4.9.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.4.9.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.4.9.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.4.10 South Korea
8.4.10.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.4.10.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.4.10.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.4.10.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.5 Latin America
8.5.1 Market size, by country, 2017 - 2030 (USD Million)
8.5.2 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.5.3 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.5.4 Market size, by medication type, 2017 - 2030 (USD Million)
8.5.5 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.5.6 Brazil
8.5.6.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.5.6.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.5.6.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.5.6.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.5.7 Mexico
8.5.7.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.5.7.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.5.7.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.5.7.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.6 Middle East & Africa
8.6.1 Market size, by country, 2017 - 2030 (USD Million)
8.6.2 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.6.3 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.6.4 Market size, by medication type, 2017 - 2030 (USD Million)
8.6.5 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.6.6 Saudi Arabia
8.6.6.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.6.6.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.6.6.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.6.6.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.6.7 South Africa
8.6.7.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.6.7.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.6.7.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.6.7.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
8.6.8 UAE
8.6.8.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
8.6.8.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
8.6.8.3 Market size, by medication type, 2017 - 2030 (USD Million)
8.6.8.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
Chapter 9 Company Profiles
9.1 Competitive dashboard, 2021
9.2 Johnson and Johnson Services, Inc.
9.2.1 Business overview
9.2.2 Financial data
9.2.3 Drug formulation landscape
9.2.4 Strategic outlook
9.2.5 SWOT analysis
9.3 Alcon Inc.
9.3.1 Business overview
9.3.2 Financial data
9.3.3 Drug formulation landscape
9.3.4 Strategic outlook
9.3.5 SWOT analysis
9.4 OASIS Medical
9.4.1 Business overview
9.4.2 Financial data
9.4.3 Drug formulation landscape
9.4.4 Strategic outlook
9.4.5 SWOT analysis
9.5 Allergan (AbbVie Inc.)
9.5.1 Business overview
9.5.2 Financial data
9.5.3 Drug formulation landscape
9.5.4 Strategic outlook
9.5.5 SWOT analysis
9.6 Prestige Consumer Healthcare Inc.
9.6.1 Business overview
9.6.2 Financial data
9.6.3 Drug formulation landscape
9.6.4 Strategic outlook
9.6.5 SWOT analysis
9.7 Santen Pharmaceutical Co., Ltd.
9.7.1 Business overview
9.7.2 Financial data
9.7.3 Drug formulation landscape
9.7.4 Strategic outlook
9.7.5 SWOT analysis
9.8 Bausch Health Companies Inc.
9.8.1 Business overview
9.8.2 Financial data
9.8.3 Drug formulation landscape
9.8.4 Strategic outlook
9.8.5 SWOT analysis
9.9 Aurolab
9.9.1 Business overview
9.9.2 Financial data
9.9.3 Drug formulation landscape
9.9.4 Strategic outlook
9.9.5 SWOT analysis
9.10 Otsuka Pharmaceutical Co.,Ltd.
9.10.1 Business overview
9.10.2 Financial data
9.10.3 Drug formulation landscape
9.10.4 Strategic outlook
9.10.5 SWOT analysis
9.11 Sentiss Pharma Pvt. Ltd.
9.11.1 Business overview
9.11.2 Financial data
9.11.3 Drug formulation landscape
9.11.4 Strategic outlook
9.11.5 SWOT analysis
9.12 Sun Pharmaceutical Industries Ltd.
9.12.1 Business overview
9.12.2 Financial data
9.12.3 Drug formulation landscape
9.12.4 Strategic outlook
9.12.5 SWOT analysis
9.13 URSAPHARM Arzneimittel GmbH
9.13.1 Business overview
9.13.2 Financial data
9.13.3 Drug formulation landscape
9.13.4 Strategic outlook
9.13.5 SWOT analysis
